The Cooper Companies, Inc. $COO Shares Purchased by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its stake in The Cooper Companies by 11.0%, owning 131,342 shares valued at $9.35 million after purchasing an additional 13,011 shares.
• The Cooper Companies reported $1.10 earnings per share for the quarter, exceeding analysts' expectations of $1.07, with revenues up 5.7% compared to the same period last year.
• The company has authorized a $2 billion stock repurchase plan, indicating a belief that its stock is undervalued, which allows for buying back up to 15.4% of its shares.

Aberdeen Group plc raised its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 11.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 131,342 shares of the medical device company's stock after buying an additional 13,011 shares during the quarter. Aberdeen Group plc owned about 0.07% of Cooper Companies worth $9,346,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Blue Trust Inc. grew its holdings in Cooper Companies by 24.7% during the 2nd quarter. Blue Trust Inc. now owns 1,362 shares of the medical device company's stock valued at $97,000 after buying an additional 270 shares during the last quarter. Triodos Investment Management BV grew its holdings in Cooper Companies by 37.0% during the 2nd quarter. Triodos Investment Management BV now owns 248,000 shares of the medical device company's stock valued at $17,648,000 after buying an additional 67,000 shares during the last quarter. Baldwin Wealth Partners LLC MA grew its holdings in Cooper Companies by 1.7% during the 2nd quarter. Baldwin Wealth Partners LLC MA now owns 167,391 shares of the medical device company's stock valued at $11,912,000 after buying an additional 2,810 shares during the last quarter. Callan Family Office LLC grew its holdings in Cooper Companies by 12.7% during the 2nd quarter. Callan Family Office LLC now owns 4,365 shares of the medical device company's stock valued at $311,000 after buying an additional 493 shares during the last quarter. Finally, Vontobel Holding Ltd. grew its holdings in Cooper Companies by 32.5% during the 2nd quarter. Vontobel Holding Ltd. now owns 8,137 shares of the medical device company's stock valued at $579,000 after buying an additional 1,994 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.

Cooper Companies Price Performance

Shares of Cooper Companies stock opened at $68.76 on Thursday. The Cooper Companies, Inc. has a twelve month low of $61.78 and a twelve month high of $109.04. The stock has a market capitalization of $13.67 billion, a P/E ratio of 33.87, a PEG ratio of 1.87 and a beta of 1.02. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The business's fifty day moving average price is $69.43 and its 200 day moving average price is $73.43.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter last year, the firm earned $0.96 earnings per share. The firm's revenue for the quarter was up 5.7% compared to the same quarter last year. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies declared that its board has approved a stock repurchase plan on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Insider Transactions at Cooper Companies

In related news, EVP Brian G. Andrews acquired 1,525 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were bought at an average cost of $65.68 per share, with a total value of $100,162.00. Following the completion of the transaction, the executive vice president directly owned 22,191 shares of the company's stock, valued at $1,457,504.88. This trade represents a 7.38% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Albert G. White III acquired 10,000 shares of the business's stock in a transaction on Friday, September 5th. The stock was bought at an average cost of $68.39 per share, for a total transaction of $683,900.00. Following the completion of the transaction, the chief executive officer directly owned 226,151 shares of the company's stock, valued at $15,466,466.89. This trade represents a 4.63% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 17,975 shares of company stock valued at $1,216,346 in the last ninety days. Company insiders own 1.98% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a "hold (c-)" rating on shares of Cooper Companies in a report on Wednesday, October 8th. BNP Paribas upgraded Cooper Companies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 22nd. JPMorgan Chase & Co. decreased their price objective on Cooper Companies from $76.00 to $66.00 and set a "neutral" rating on the stock in a report on Thursday, August 28th. Wall Street Zen cut Cooper Companies from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Finally, Needham & Company LLC restated a "buy" rating and set a $94.00 price objective on shares of Cooper Companies in a report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.